| Filed On | Filing |
|---|---|
| 15 Oct 2026 |
8-K: Regulation FD Disclosure
On October 15, 2026, Ernexa Therapeutics Inc., a Delaware corporation (the “Company”, “we”, “us”, or “our”), made available a presentation for investors. A copy of the presentation is attached hereto as Exhibit 99.1 and incorporated by r... |
| 16 Sep 2026 |
8-K: Regulation FD Disclosure
On September 16, 2026, Ernexa Therapeutics Inc., a Delaware corporation (the “Company”, “we”, “us”, or “our”), made available the corporate fact sheet and a presentation for investors. Copies of the corporate fact sheet and the presentat... |
| 16 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 02 Jul 2026 |
8-K: Regulation FD Disclosure
On July 2, 2026, Ernexa Therapeutics Inc., a Delaware corporation (the “Company”, “we”, “us”, or “our”), made available an updated presentation for investors. This presentation updates the presentation posted on February 26, 2026. A copy... |
| 02 Jul 2026 |
8-K: Submission of Matters to a Vote of Security Holders
1.1 Effective Date of the Plan. The Ernexa Therapeutics Inc. Omnibus Equity Incentive Plan (the “Plan”) was adopted by the Board of Ernexa Therapeutics Inc., a Delaware corporation (the “Company”), on May 6, 2026, subject to approval by ... |
| 26 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 04 May 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF ernexa therapeutics Inc. |
| 20 Mar 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
| 26 Feb 2026 |
8-K: Regulation FD Disclosure
On February 26, 2026, Ernexa Therapeutics Inc., a Delaware corporation (the “Company”, “we”, “us”, or “our”), made available an updated presentation for investors. This presentation updates the presentation posted on December 11, 2025. A... |
| 11 Feb 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
This Securities Purchase Agreement (this “Agreement”) is dated as of February 6, 2026, between Ernexa Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, includin... |
| 11 Dec 2025 |
8-K: Regulation FD Disclosure
On December 11, 2025, Ernexa Therapeutics Inc., a Delaware corporation (the “Company”, “we”, “us”, or “our”), made available a new presentation for investors. A copy of this presentation is attached hereto as Exhibit 99.1 and incorporate... |
| 07 Jul 2025 |
8-K: Changes in Registrant's Certifying Accountant
We have read Item 4.01 of Form 8-K of Ernexa Therapeutics Inc. dated June 30, 2025, and agree with the statements concerning our Firm contained therein. |
| 12 Jun 2025 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF ernexa therapeutics Inc. |
| 09 Jun 2025 |
8-K: Unregistered Sales of Equity Securities; Other Events
The information in Item 8.01 of this report is incorporated by reference into this Item 3.02. |
| 02 Jun 2025 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
Ernexa Therapeutics Inc. (the “Corporation”), a Delaware corporation, does hereby certify that: |
| 03 Apr 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This Securities Purchase Agreement (this “Agreement”) is dated as of March 31, 2025, between Ernexa Therapeutics Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including i... |
| 26 Mar 2025 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
The registered office of the Corporation shall be in the City of Wilmington, County of New Castle, State of Delaware. The name of the registered agent of the Corporation at such location is Corporate Agents, Inc. |
| 24 Mar 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, ETERNA THERAPEUTICS INC, a Delaware corporation (the “Maker”), hereby unconditionally promises to pay to the order of Charles Cherington or his assigns (the “N... |
| 12 Mar 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, ETERNA THERAPEUTICS INC, a Delaware corporation (the “Maker”), hereby unconditionally promises to pay to the order of Charles Cherington or his assigns (the “N... |
| 13 Feb 2025 |
8-K: Shareholder Director Nominations
On February 7, 2025, the board of directors of Eterna Therapeutics Inc. (the “Company”) set the date for the Company’s 2025 annual meeting of stockholders (the “Annual Meeting”) for May 1, 2025, which is more than 30 calendar days before... |
Loading...